Yuanyuan Zha

TL;DR: The results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients and could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti–PD-L1 therapy.

TL;DR: The results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell–inflamed tumor microenvironment.

TL;DR: The results suggest that lack of critical chemokines in a subset of melanoma metastases may limit the migration of activated T cells, which in turn could limit the effectiveness of antitumor immunity.

TL;DR: In this paper, the safety of pembrolizumab with multisite Stereotactic Body Radiotherapy (SBRT) was evaluated in patients with metastatic solid tumors.

TL;DR: Preliminary clinical success is validating this working model, suggesting that two major categories of immune resistance within the tumor microenvironment may exist: failure of T cell trafficking due to low levels of inflammation and lack of chemokines for migration, and dominant suppression through immune inhibitory mechanisms.